Table 4.

Pearson's correlation coefficients between absolute change in treatment‐induced sparing volume and the absolute change in MRI and clinical measurements

Specific clinical measurements	All (111)	Estriol + GA (62)	Placebo + GA (49)
Whole GM volume	0.84***	0.89***	0.77***
Cortical GM volume	0.53***	0.54***	0.46***
WM volume	−0.23 *	−0.27*	−0.21
CSF volume	−0.59***	−0.65***	−0.51***
Gd‐enhancing lesion volume	−0.03	−0.07	0.11
FLAIR lesion volume	0.03	0.04	−0.13
PASAT3	0.20*	0.31*	−0.34*
PASAT2	0.31**	0.34**	0.08
9HPT	−0.09	−0.21	0.09
T25FW	−0.01	0.06	−0.19
MSFC	0.15	0.22	−0.06
EDSS	0.02	0.02	0.03

CSF, cerebrospinal fluid; EDSS, expanded disability status scale; FLAIR, fluid‐attenuated inversion recovery; GA, glatiramer acetate; Gd, gadolinium; GM, gray matter; MRI, magnetic resonance imaging; MSFC, multiple sclerosis functional composite; PASAT2, paced auditory serial addition test at 2 s; PASAT3, paced auditory serial addition test at 3 s; T25FW, timed 25‐foot walk; WM, white matter; 9HPT, 9‐hole peg test.

*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.